Peptides
Cagrilintide for weight loss: what the trials actually show
Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone involved in satiety. It is being studied as a weight-management medicine on its own and with semaglutide. These are separate questions: results for the combination cannot be credited entirely to cagrilintide. [1,2]
How does it work?
Amylin signaling helps people feel full and can slow food intake. Cagrilintide is designed to act on this pathway for longer than natural amylin. The clinical endpoint is body-weight change measured in randomized trials, not a claim that any vial produces the same effect. [1]
What did human trials find?
A 26-week randomized phase 2 trial enrolled 706 adults with obesity, or overweight plus a related risk factor, without diabetes. Once-weekly cagrilintide groups lost an estimated 6.0%–10.8% of starting weight across studied doses under the trial-product analysis, compared with 3.0% in the pooled placebo group. Participants received lifestyle advice and dose escalation. The study was funded by the manufacturer. [1]
The larger 68-week REDEFINE 1 trial included cagrilintide alone, semaglutide alone, their fixed combination, and placebo. The cagrilintide-only arm supported a weight-loss signal, while the combination produced more weight loss than either component alone. The headline combination number must not be presented as a cagrilintide-only result. [2]
Side effects and evidence limits
Nausea, constipation, diarrhea, and injection-site reactions were common in the phase 2 study. Forty-one to 63 percent of cagrilintide participants reported gastrointestinal events versus 32 percent with placebo. Longer studies inform the development program, but a research-market product has not been shown to match the tested formulation, stability, sterility, or dose delivery. [1,2]
STUDIED AMOUNT
How much?
SOURCE CONTEXT
What it refers to
studied investigational amount in the cagrilintide-only arm of REDEFINE 1, given subcutaneously with gradual escalation in a clinical trial.
2.4 mg once weekly — studied investigational amount in the cagrilintide-only arm of REDEFINE 1, given subcutaneously with gradual escalation in a clinical trial. The earlier phase 2 study tested a range from 0.3 to 4.5 mg once weekly over 26 weeks. These are study designs, not interchangeable starting doses or an approved schedule. [1,2]
Read detailed dosing notes
No safe and effective dose for the catalog vial has been established. A prescribed weight-management plan should use a regulated medicine and clinical assessment rather than transfer a trial schedule to an unverified vial. [1,2]